Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Abuse, Misuse, and Addiction
Educate patients and their families about the risks of abuse, misuse, and addiction of Methylphenidate HCl Extended-Release Tablets, which can lead to overdose and death, and proper disposal of any unused drug [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.1, 9.2), Overdosage (10)]. Advise patients to store Methylphenidate HCl Extended-Release Tablets in a safe place, preferably locked, and instruct patients to not give Methylphenidate HCl Extended-Release Tablets to anyone else.
Risks to Patients with Serious Cardiac Disease
Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with Methylphenidate HCl Extended-Release Tablets use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease [see Warnings and Precautions(5.2)].
Increased Blood Pressure and Heart Rate
Advise patients and their caregivers that Methylphenidate HCl Extended-Release Tablets can cause elevations in blood pressure and heart rate [see Warnings and Precautions (5.3)].
Psychiatric Risks
Advise patients and their caregivers that Methylphenidate HCl Extended-Release Tablets, at recommended doses, can cause psychotic or manic symptoms, even in patients without a prior history of psychotic symptoms or mania [see Warnings and Precautions (5.4)].
Priapism
Advise patients, caregivers, and family members of Methylphenidate HCl Extended-Release Tablets-treated males of the possibility of priapism. Instruct the patient to seek immediate medical attention in the event of priapism [see Warnings and Precautions (5.5)].
Peripheral Vasculopathy, including Raynaud’s Phenomenon
Instruct patients about the risk of peripheral vasculopathy, including Raynaud’s phenomenon, and associated signs and symptoms; to report to their health care provider any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes; to call their health care provider immediately with any signs of unexplained wounds appearing on fingers or toes while taking Methylphenidate HCl Extended-Release Tablets [see Warnings and Precautions (5.6)].
Long-term Suppression of Growth in Pediatric Patients
Advise patients, caregivers, and family members that Methylphenidate HCl Extended-Release Tablets may cause slowing of growth and weight loss in pediatric patients [see Warnings and Precautions (5.7)].
Glaucoma and Increased Intraocular Pressure
Advise patients that increased intraocular pressure and glaucoma may occur during Methylphenidate HCl Extended-Release Tablets treatment [see Warnings and Precautions (5.10)].
Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
Advise patients that motor and verbal tics and worsening of Tourette’s Syndrome may occur during Methylphenidate HCl Extended-Release Tablets treatment. Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Tourette’s syndrome occurs [see Warnings and Precautions (5.11)].
Administration Instructions
Instruct patients to swallow Methylphenidate HCl Extended-Release Tablets whole with liquids, and not to split, crush, or chew, the extended-release tablets.
Pregnancy
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Methylphenidate HCl Extended-Release Tablets during pregnancy [see Use in Specific Populations (8.1)].
Lactation
Advise Methylphenidate HCl Extended-Release Tablets-treated breastfeeding women to monitor their infants for agitation, poor sleeping patterns, changes in feeding, and reduced weight gain [see Use in Specific Populations (8.2)].